Tenaya Therapeutics, Inc.
TNYA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1,864 | $2,084 | $0 | $0 |
| Gross Profit | -$1,864 | -$2,084 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $15,363 | $17,370 | $21,076 | $18,688 |
| G&A Expenses | $0 | $6,712 | $6,462 | $5,964 |
| SG&A Expenses | $3,709 | $6,712 | $6,462 | $5,964 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$2,084 | $0 | $0 |
| Operating Expenses | $19,072 | $21,998 | $27,538 | $24,652 |
| Operating Income | -$20,936 | -$24,082 | -$27,538 | -$24,652 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $661 | $799 | $674 | $816 |
| Pre-Tax Income | -$20,275 | -$23,283 | -$26,864 | -$23,836 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$20,275 | -$23,283 | -$26,864 | -$23,836 |
| % Margin | – | – | – | – |
| EPS | -0.12 | -0.14 | -0.24 | -0.28 |
| % Growth | 14.3% | 41.7% | 14.3% | – |
| EPS Diluted | -0.12 | -0.14 | -0.24 | -0.28 |
| Weighted Avg Shares Out | 163,346 | 162,792 | 109,869 | 86,406 |
| Weighted Avg Shares Out Dil | 163,346 | 162,792 | 109,869 | 86,406 |
| Supplemental Information | – | – | – | – |
| Interest Income | $658 | $815 | $635 | $812 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1,864 | $2,084 | $2,661 | $2,089 |
| EBITDA | -$18,411 | -$21,199 | -$24,877 | -$22,563 |
| % Margin | – | – | – | – |